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Abstract 
BACKGROUND: Severe pain is one of the major problems in patients with leg bone fracture. Various methods 
have been proposed to relieve pain. Opioids are one of the most important available medications to control these 
types of pain. Among the opioids available, fentanyl can be applied for its unique properties as transdermal 
patches.  
AIM: Therefore, the current study aimed to investigate the effect of intravenous morphine and fentanyl skin patch 
in patients with a lower leg fracture.  
METHODS: We entered 60 patients in this randomised, one-blind randomised clinical trial among patients 
referring to the emergency department of Vali-e-Asr Hospital in Arak with a fracture of the leg. Demographic and 
clinical data were recorded for patients. The case group (n = 30) received the fentanyl patch in the same area. 
Patients in the control group (30) received 0.1mcg/kg of morphine intravenously. In both groups, the severity of 
pain was measured every 20 minutes within two hours after onset of treatment based on VAS criteria and 
subsequently recorded in the checklist. Data were analysed by SPSS v.22 software package. 
RESULTS: The results of the present study demonstrated that the mean visual analogue scale (VAS) pain score 
at minutes 20, 40, 60 and 80 were statistically lower in intervention group when compared with the control group 
(p = 0.000). 
CONCLUSION: Our results indicated a considerable risk-benefit profile for the treatment of pain in patients 
suffering from dysphagia, nausea and vomiting, or resistance to other opioids. The use of fentanyl patch is also 
suitable for patients who are not able to take their medication at their scheduled time. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The increasing use of machinery and vehicles 
has led to vehicle-related accidents and serious 
physical injuries, which has become a major health 
problem for humans. Due to the occurrence of 
accidents at high speeds, vehicle-related injuries are a 
considerable risk of provoking a severe complication 
and often results in disability, amputation and death of 
the injured patients. One of the most common causes 
of amputation is open fractures, one of the most 
common causes of amputation is open fractures, most 
commonly occurring in the legs of 21.9% [1] and 
consisting 25% of open fractures [2]. 
On the one hand, the type of soft tissue injury 
causes acute and life-threatening infections in open 
fractures; on the other, creates chronic and resistant 
bone infection [3]. Leg bone fractures (tibia and fibula 
fractures) are the most common bone fracture in the 
body that occurs in the majority of men at younger 
ages [4], due to the low soft tissue coverage in 
anterior and anteromedial parts and inadequate blood 
supply and soft tissue in this area [5]; whereas tibia 
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nonunion account for the highest percentage of total 
referrals [6]. Pain is one of the most preventable 
complications in surgeries, but usually, it is not 
enough to treat it. Pain can indirectly increase 
morbidity and mortality, while also contributing to 
increased costs and lower quality of life. 
Pain relief is a challenge after surgery, which 
requires pain relievers with minimal side effects and 
the highest level of safety for the patient [7]. Currently, 
postoperative pain treatment has been highly 
considered. Some studies have reported a high 
prevalence of postoperative pain. Severe pain not 
only causes pain and discomfort but also prevent 
patients from returning to daily activities, which is 
considered an important socio-economic factor [8]. 
Severe pain is one of the major problems for 
patients with leg bone fracture. Various methods have 
been proposed to relieve pain associated with bone 
fracture. Opioids can be mentioned as the most 
important compounds with the most availability 
regarding controlling this type of pain. Pain control 
using oral and intravenous opioids requires effective 
dosage and regular use of medications. In most 
cases, regular use of these compounds may be 
difficult due to problems with patient’s problem and 
forgetfulness and ultimately leads to insufficient 
control of the patient's pain.  
Therefore, various methods have been 
introduced for transferring the drug, which can be 
referred to transdermal adhesives [9]. Among the 
opioids available, fentanyl can be applied for its 
unique properties as transdermal patches 
(adhesives). Fentanyl has been considered as an 
artificial opioid due to its fatty properties and high 
analgesic power compared to morphine in the 1990s 
[10]. Fentanyl transdermal patch can be effectively 
used, especially for patients suffering from dysphagia, 
nausea and vomiting, or resistance to treatment, or 
intolerance to other opioids.  
Also, this method is appropriate for patients 
who are not able to take their medication at the 
prescribed time [11]. Fentanyl is an artificial opiate 
drug that was first made in 1960 and has been used 
as part of the anaesthetic regimen for about 30 years. 
Physical properties of the drug include low molecular 
weight, high solubility in fat and high power, which has 
led to the use of fentanyl in transdermal drug delivery 
systems [12]. There is a controversy about the 
effectiveness of the fentanyl skin patch method, where 
some studies have not yet succeeded in exhibiting 
this effect well. The researchers attribute the causes 
of these differences to the differences in the 
methodology and quality of the studies, as well as 
sample sizes and comparison groups. 
The current study aimed to compare the 
effectiveness of the fentanyl transdermal patch with 
the effect of intravenous morphine in patients. 
Material and Methods 
 
We enrolled 60 (43 man and 17 women) in 
this, single-blind randomised controlled clinical trial. 
The statistical population consisted of patients who 
referred to the emergency department of Vali-e-Asr 
Hospital in Arak, with a fracture of the leg. All of them 
were in the first and second classes (ASA II and I) of 
the American Society of Anesthesiologists (ASA). The 
primary diagnosis was based on four criteria including 
localised tenderness, pain, deformity, and crepitation. 
Patients were entered the treatment groups using a 
random number table after filling the inclusion criteria. 
The primary examination of the patient was done by a 
specialist, and the final diagnosis was performed by 
the two physicians. Early demographic and clinical 
characteristics of patients were recorded. The 
patients' pain was then checked by the VAS criteria 
and data recorded in the checklist. 
In the case group (30 patients), subjects 
received the fentanyl transdermal patches in the same 
areas. The patch placement includes 1: left deltoid 
muscle; 2: right deltoid muscle; 3: left chest on the top 
of the nipple; 4: right chest on the top of the nipple. 
In the control group (30 patients), subjects 
also received 0.1 mcg/kg of morphine intravenously. 
In both groups, pain intensity was measured 
every 20 minutes during two hours after treatment 
based on VAS criteria and finally recorded in the 
checklist. 
All data were analysed by SPSS v.22 
software package. To present the results, mean 
indexes, standard deviation, standard error, the 
percentage of frequency were applied. Furthermore, 
tests such as covariance analysis, Chi-square, 
Independent T-test or its nonparametric equivalents 
were employed to compare the means. P < 0.05 was 
considered as statistically significant. 
Inclusion criteria included the age of over 18 
years, patients with leg fractures, obtaining an 
informed consent form, 
Exclusion criteria include Patients' refusal to 
participate in the study, the failure to diagnose 
fractures in the radiographic images, the incidence of 
complications and the sensitivity to the drug 
administration, and the history of related diseases, as 
well as the transferring the patient to the operating 
room within two hours after entering the emergency 
room. 
The informed consent of the participation in 
the study was taken optionally, and the confidentiality 
of the information was retained. This research project 
was approved by the Ethics Committee of the 
Research Council of Arak University of Medical 
Sciences with the number 2792 (ethics code: 
IR.ARAKMU.REC.1395.298). 
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Results 
 
Of the 30 patients in the experimental group, 
20 were men (66.6%) and the rest were women. Also, 
the control group consisted of 23 male patients 
(76.7%) and 17 female patients. To test the 
homogeneity of the two groups, Chi-square test was 
applied, where showed no significant difference in 
both groups (P = 0.22). In the test group, the majority 
of patients (73.3%) were in the age group of 21-30 
years, while the lowest frequency (3. 3%) was in the 
age group of fewer than 20. Moreover, most of the 
patients in the control group (70%) were seen in the 
age group of 20-30 years, and the lowest (6.7%) 
belonged to the age group of fewer than 20 years old. 
Based on the Fisher test, the two groups did not 
exhibit a significant difference in age (P = 0.42). Base 
on the use of t-test, there was no significant difference 
between the mean VAS pain score at 0 minutes (P = 
0.37) in both groups. There was no significant 
difference between the two groups regarding the vital 
signs of the patients (Table 1). 
Table 1: Comparison of pain intensity and vital signs at zero 
minute 
Variable  Fentanyl Morphine Analysis text 
VAS 66.±66.9  87.±7  0.370 
O2saturation 06.3±36.99  59.3±36.99  0.100 
BP 09.1±63.13  19.1±83.13  0.710 
T 59.±38  13.±61.38  0.09 
RR 87.5±36.00  36.9±36.01  0.140 
PR 66.9±93.97  59.3±96.99  0.140 
 
Using t-test, the mean VAS pain score at 20 
minutes in both groups was significantly different (P = 
0.000). A pain score of the morphine group 
significantly decreased more than the other group. 
Furthermore, the vital signs of the patients in both 
groups were evaluated using a t-test, where the 
findings did not emphasise the significant difference 
between the two groups (Table 2). 
Table 2: Comparison of pain severity and vital signs in the 20 
the minute 
Variable Fentanyl Morphine Analysis text 
VAS 66.±95.7  69.±06.5  0.000 
O2saturation 08.1±03.96  58.1±03.96  0.640 
BP 19.1±83.13  95.1±71.13  0.770 
T 18.±98.36  59.±38  0.730 
RR 87.5±56.00  90.5±56.00  1.000 
PR 59.3±93.96  66.9±56.97  0.270 
 
The mean VAS pain score in both groups was 
statistically significant at 40 minutes (P = 0.000); in 
other words, the mean VAS pain score of morphine 
group was markedly decreased as compared to 
another group. There was no significant difference 
between the two groups regarding O2 saturation, RR 
and PR in both groups. However, we found that the 
mean of BP and T in both groups was statistically 
different from t-test (Table 3). 
 
Table 3: Comparison of severity of pain and vital signs in 40 
the minute 
Variable Fentanyl Morphine Analysis text 
VAS 90.±06.9  86.±01.5  0.000 
O2saturation 98.1±36.93  08.1±03.96  0.310 
BP 61.9±05.10  59.1±76.13  0.000 
T 19.±99.36  05.±7.36  0.002 
RR 69.6±36.01  87.5±56.00  0.460 
PR 80.3±06.96  66.9±93.97  0.190 
 
As shown in Table 4, the mean pain score 
(VAS) of 60 minutes was lower in the morphine group 
than in the fentanyl group (P = 0.000). There was no 
significant difference between the two groups 
regarding O2saturation, RR, and PR symptoms in 
both groups. However, the mean values of P and T in 
both groups were significantly different based on the 
T-test. 
Table 4: Comparison of the severity of pain and vital signs in 
the 60th minute 
Variable Fentanyl Morphine Analysis text 
VAS 89.±1.5  89.±16.3  0.000 
O2saturation 8.10±03.96  31.1±06.96  0.920 
BP 91.0±01.10  5.1±91.13  0.001 
T 01.±98.36  00.±76.36  0.005 
RR 87.9±63.06  87.5±56.00  0.200 
PR 86.±73.99  69.1±56.97  0.140 
 
Table 5 demonstrated a significant difference 
between the mean VAS pain score at 80 minutes in 
both groups (P = 0.000). Also, there were no 
significant differences in O2 saturation, RR, and PR 
symptoms in both groups. However, the mean value 
of BP and T in both groups was remarkably different 
(Table 5).  
Table 5: Comparison of pain severity and vital signs in the 80th 
minute 
Variable Fentanyl Morphine Analysis text 
VAS 83.±66.5  88.±03.3  0.000 
O2saturation 18.0±36.96  31.1±06.96  0.760 
BP 67.0±11.10  56.1±86.13  0.002 
T 01.±98.36  00.±76.36  0.005 
RR 90.9±93.06  76.5±53.00  0.280 
PR 79.3±9.96  66.9±56.97  0.170 
 
As indicated in Table 6, the mean VAS pain 
score for 100th minutes in the fentanyl group was less 
than the other group (P = 0.000). On the other hand, 
there were no significant differences in the O2 
saturation, RR, and PR in both groups. However, the 
mean value of BP and T in both groups revealed a 
significant difference by using t-test. 
Table 6: Severity of pain and vital signs in the 100th minute 
Variable Fentanyl Morphine Analysis text 
VAS 96.±96.3  88.±13.5  0.001 
O2saturation 01.1±36.96  06.1±33.96  0.920 
BP 56.0±55.10  57.1±79.13  0.000 
T 06.±96.36  03.±79.36  0.005 
RR 61.1±99.01  79.±16.00  0.620 
PR 19.9±65.95  6.9±93.98  0.009 
 
Our results revealed that the mean VAS pain 
score in the 100th minute in the fentanyl group was 
not significantly different compared with morphine 
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group (P = .000). We did not find a significant 
difference in the vital signs of O2 saturation, RR and 
PR in patients in both groups. Nevertheless, the mean 
values of BP and T in both groups were significantly 
different by using T-test (Table 7). 
Table 7: Comparison of severity of pain and vital signs in 120 
the minute 
Variable Morphine Fentanyl Analysis text 
VAS 36.±66.3  86.±63.5  0.000 
O2saturation 00.0±79.96  58.1±56.96  0.270 
BP 59.6±50.10  05.9±70.13  0.000 
T 09.±95.36  00.±56.36  0.050 
RR 79.5±36.06  79.5±93.00  0.080 
PR 18.5±16.99  67.9±66.97  0.060 
 
We compared the mean VAS pain at minutes 
0 to 120 in the two groups of fentanyl and morphine. 
The results exhibited that there was no significant 
difference between the two groups in only 0 minutes, 
but in the remaining minutes, this difference was 
statistically significant (Table 8). 
Table 8: VAS pain score at minutes 0 to 120 
Variable Fentanyl Morphine Analysis text 
VAS0 66.±66.9  87.±7  0.370 
VAS20 66.±95.7  69.±06.5  0.000 
VAS40 90.±06.9  86.±01.5  0.000 
VAS60 89.±1.5  89.±16.3  0.000 
VAS80 83.±66.5  88.±03.3  0.000 
VAS100 96.±96.3  88.±13.5  0.001 
VAS120 36.±66.3  86.±63.5  0.000 
 
 
 
Discussion 
 
In this clinical trial study, 60 patients were 
randomly divided into intervention and control groups 
during 2017 in Valiasr Hospital. The study showed 
that the oldest person in the intervention group was 94 
years old, and the youngest was 49 years old. 
Moreover, the oldest person in the control group 
belonged to a 64 years old individual and the 
youngest person was 16 years old. Using statistical 
tests, the mean age of the two groups was not found 
to be significantly different (p = 0.42). 
Furthermore, the mean height of the subjects 
in the intervention group was determined to be 6.2 ± 
1.71. In the intervention group, the mean height of the 
patients was calculated as 15.60 ± 1.69. There was 
no statistically significant difference between the 
mean height of the control and intervention groups (p 
= 0.12). This study aimed to compare the pain in 
patients with fracture of the leg in the use of fentanyl 
skin patches and injectable morphine ampoule. Before 
the onset of the intervention, by comparing the pain 
with VAS scores, it was revealed that the mean score 
of pain in both groups was not significantly different 
(P-value = 37.7). 
Regarding the random sampling and the 
similarity of pain between the two groups, the pain 
was accordingly the same between the two groups 
before each intervention. Based on the results 
presented in this study, the pain score between the 
two intervention and treatment groups was statistically 
significant at 20, 40, 60 and 80 minutes, so that the 
pain score of the control group (morphine) was lower 
than that of the intervention group (P = 0.000). In 
other words, morphine has been able to produce more 
analgesic effects at these times. The onset of 
analgesic effect of intravenous morphine  (0.1-0.05 
mg.kg) is 10-20 minutes after injection, but the onset 
of analgesic effect of fentanyl skin patch could be 
started after one hour [13]. 
Also, fentanyl patch is not predictable, which 
its effects may be started up to several hours, 
depending on the body temperature, and the previous 
dose of the drug, as well as other factors such as the 
location of use, hemodynamics and the general 
condition of the patient (fragility, hypovolemia). 
Absorption continues for a few hours 
unpredictably following removal of the patch [14]. 
These results are consistent with our findings. Also, 
due to the slow start of fentanyl absorption, patients 
may use a patch from the day before surgery. 
Localised blood flow to the patch site can affect the 
absorption of the drug. Heat blankets, moisture or 
sepsis, can increase blood flow to the skin, leading to 
an increase in total systemic absorption [14]. The 
results of our study demonstrated that the mean score 
of pain at 100 and 120 minutes was significantly 
different, where the mean score of pain in the 
intervention group was significantly lower as 
compared to the control group (p = 0.00). In other 
words, patients in the intervention group who used 
fentanyl skin patch had less pain after one hour than 
those in the control group. The unique properties of 
fentanyl include its 75-fold strength compared to 
morphine, low molecular weight, and lipophilicity, as 
well as higher skin absorption capacity than morphine. 
Inconsistent with our results, these features 
reduce pain by initiating the effect of fentanyl [15]. In 
2004, Clark found that the analgesic effect of fentanyl 
skin patch was significantly higher than that of 
morphine [16], which is in agreement with our results. 
In another study by Hemmati et al., The results 
showed that fentanyl skin patch significantly reduced 
the pain of patients with soft tissue tumours compared 
to placebo [17]. Another study evaluated the safety 
and therapeutic effect of 12-month use with fentanyl 
patch. This mentioned study indicated a reasonable 
risk-benefit profile for managing moderate to severe 
chronic pain in non-cancer patients treated with 
fentanyl patch under long-term compared with 
patients who treated with other opiate drugs. 
Respiratory depression, drug dependence, and drug 
discontinuation were rarely observed in patients [18]. 
Some of the properties of the drug that leads 
to better tolerance of the drug by the patient, its 
effectiveness and its relative safety include the need 
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for repeated administration of the drug, lower peak 
plasma concentration, and lack of liver first pass 
metabolism [19]. In patients with cancer pain, the use 
of this drug leads to prolonged and effective 
analgesia. Four different drug types are available 
including 25, 50, 75 and 100 micrograms per hour.  
The fentanyl patch needs 24 to 72 hours to 
reach a sustained level of blood, and absorption of 
remaining fentanyl lasts for several hours after 
removing the patch. After removing the fentanyl patch, 
it takes about 17 hours to reduce the plasma 
concentration of the drug by 50%. Therefore, there is 
a potential for drug interruption with anaesthetics, 
sleep apnea and other opioids several hours after 
removing the patch. Therefore, the risk of drug 
interruption is not eliminated immediately following the 
removal of the patch. It is worth noting that the 
fentanyl patch releases the drug for up to 72 hours 
and has been proposed as a synthetic drug with short-
term analgesia [20]. 
On the other hand, fentanyl provides an 
appropriate plasma concentration up to 72 hours, 
where the blood concentration of the drug gradually 
increases, leading to a reduced risk of complications. 
Fentanyl metabolites are not pharmacologically active 
and are not affected by the liver first pass metabolism 
or gastrointestinal absorption. Fentanyl with a high 
tendency and specifically binds to the μ2-opioid 
receptor. Therefore, the side effects of activating the 
μ2-opioid receptor such as nausea, vomiting and 
constipation that is seen with the use of morphine are 
not seen with this drug. It should be taken into 
consideration that the complications of accumulation 
of metabolites are not seen in patients receiving this 
drug [21].  
In summary, this study exhibited that the 
fentanyl skin patch has a significantly more analgesic 
effect in patients with fractures after one hour than 
morphine.  The use of transdermal fentanyl is useful 
especially for patients suffering from dysphagia, 
nausea, vomiting, or other forms of resistance to other 
opioids. It is also suitable for patients who are not able 
to take their medication at their scheduled time. 
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